How should we think about the future of psychedelic neuroscience and addiction recovery? I've talked with neuroscientist Devin Effinger, PhD, about psychedelics, neuroplasticity, addiction, and the evolving relationship between lived experience and translational neuroscience. We discussed where the science (we suppose) is heading, what questions remain unanswered, and how emerging neurotherapeutics may reshape the future of psychiatry.

Activating the 5-HT2A receptor in the prefrontal cortex engages both Gq protein and beta-arrestin signaling, each triggering distinct downstream pathways to neuroplasticity. But which of these routes actually drive therapeutic outcomes? I spoke with Jason Wallach to break it down.

What does the next phase of (nor)ibogaine development actually look like? On Friday, 05.01.26, I spoke with Dr. Deborah C. Mash about the future of ibogaine and noribogaine, from mechanism to clinical strategy.

The Pillars of a Successful IND: A live discussion with Kimberly Chew on indication, data, safety, and common failure points, particularly relevant in light of the recent Executive Order signed by the White House.

Dr. Eline Pottie shows us how to measure biased agonism at 5-HT2AR using paired bioluminescence assays, introducing the bias factor β and the power and limitations behind it. Dr. Pottie also introduces dose-dependent dual bias, and its direct implications for clinical dosing strategy.

Does PTSD heal through emotional safety or through rewriting the self? We interviewed live on LinkedIn Dr. Brandon Weiss, Assistant Professor at Johns Hopkins and PTSD specialist. We’ll explore a key question in psychedelic psychiatry: Are some forms of PTSD better treated with MDMA than psilocybin? Dr. Weiss will help us unpack these differences and how clinicians might choose between them in practice.

We had the pleasure of interviewing Nick Kadysh of PharmAla Biotech Inc. at the Psychedelic Therapeutics & Drug Development Conference in New Orleans a few weeks ago. We discussed the pipeline status of MDMA analogs and the broader trajectory of the field. As he puts it, “the wave of clinical data coming to us is unparalleled in the history of neuropsychiatry.” This interview is part of the live conference coverage by Cascades Analytics, in partnership with Arrowhead SciTech Conferences & Events.

We spoke with one of the world’s leading experts on the 5-HT2A receptor, Ryan Gumpper. As psychedelic drug development matures, the 5-HT2A receptor remains a central node in the field, not only for classical psychedelics, but increasingly for the next generation of neuroplastogens. We discuss how new research is refining our understanding of the 5-HT2AR and why it continues to anchor much of the therapeutic promise in psychedelic science. Conducted as part of Cascades Analytics’ conference coverage, in partnership with Arrowhead SciTech Conferences & Events.

Live from Day 2 of the Psychedelic Therapeutics & Drug Development Conference in New Orleans: Today, we spoke with Manesh Girn, PhD (Five Discovery) about the therapeutic potential of 5-MeO-DMT and its emerging clinical applications. Conducted as part of Cascades Analytics’ conference coverage, in partnership with Arrowhead SciTech Conferences & Events.l

Fresh insights from the Psychedelic Therapeutics & Drug Development Conference in New Orleans. In this interview, psychiatrist Brian Barnett discusses the horizon of psychedelic therapies and what it may take for these treatments to become available to patients. As psychedelic therapies approach regulatory milestones, the key question is no longer only efficacy, but how these treatments will actually be delivered safely and at scale. Part of Cascades Analytics’ live conference coverage, in partnership with Arrowhead SciTech Conferences & Events.

It was great speaking live with Joel Brierre at the Psychedelic Therapeutics & Drug Development Conference in New Orleans a few weeks ago. We discussed how Five Discovery is developing non-hallucinogenic analogs of 5-MeO-DMT, and why these compounds could open new therapeutic avenues for neurodegenerative disease and brain injury. Watch the replay to learn more about the strategy behind these next-generation neuroplastogens. Interview conducted as part of Cascades Analytics’ live coverage of PTDDC, in partnership with Arrowhead SciTech Conferences & Events.

We had the pleasure of speaking with Odette Hauke at last week’s Psychedelic Therapeutics & Drug Development Conference in New Orleans. We discussed how FDA regulatory and submission protocols are evolving, particularly with the growing integration of AI into drug development and review processes. Conducted as part of Cascades Analytics’ conference coverage, in partnership with Arrowhead SciTech Conferences & Events.

We had the privilege of speaking live a few weeks ago with Peter Hendricks, Chair of the Psychedelic Therapeutics and Drug Development Conference, who shared a clear sense of optimism about the growing wave of compounds in development: “If we have so many different tools in the toolbox, it’s likely that something will work for someone.” Part of the coverage by Cascades Analytics of the Psychedelic Therapeutics and Drug Development Conference, in partnership with Arrowhead SciTech Conferences & Events.

Live from the Psychedelic Therapeutics & Drug Development Conference in New Orleans: we had the pleasure today to speak with Josh Hardman (Psychedelic Alpha) about what excites him most right now and where he sees the field heading next. Conducted on-site as part of Cascades Analytics’ coverage of the conference in partnership with Arrowhead SciTech Conferences & Events.

We had the pleasure of speaking live with Armin Khayatian at the Psychedelic Therapeutics & Drug Development Conference about the vision behind Lionheart Ventures. We discussed how Lionheart Ventures approaches transformative technologies, and Armin shared his perspective on the evolution of the psychedelic sector, including the market response to Compass Pathways’ latest results. This conversation was recorded as part of Cascades Analytics’ on-site conference coverage, in partnership with Arrowhead SciTech Conferences & Events.

Great insights from Kevin Lanzo (Lionheart Ventures) at last week’s Psychedelic Therapeutics & Drug Development Conference in New Orleans. We discuss key developments that emerged during the conference and what they could mean for the field. Conducted as part of Cascades Analytics’ conference coverage, in partnership with Arrowhead SciTech Conferences & Events.

Great insights from Kimberly Chew at last week’s Psychedelic Therapeutics & Drug Development Conference in New Orleans. We discuss key developments that emerged during the conference and what they could mean for the field. Conducted as part of Cascades Analytics’ conference coverage, in partnership with Arrowhead SciTech Conferences & Events.

On Friday, January 30, we spoke with Alan Nafiev, Founder and CEO of Receptor.ai, about how receptor-level modeling is transforming drug discovery in neuropsychiatric disorders.

On Friday, January 9, 2026, we spoke with Prof. Alex Kwan (Cornell University) discussing a crucial shift in how we think about psychedelic plasticity: psilocybin does not increase plasticity globally, but instead selectively rewires specific cortical networks. A must-watch for anyone interested in the mechanistic future of psychedelic neuroscience.

Tuesday, November 18, 2025, we went live on LinkedIn with Sonia Weiss Pick (WPSS.bio) to explore the science, strategy, and future of psychedelic investing.

We interviewed live Nick Kadysh, CEO of PharmAla Biotech Inc. (MDMA.CSE) on LinkedIn Live. We discussed the challenges and innovations behind developing scalable, compliant processes for the supply of LaNeo™ MDMA and other novel MDXX compounds — and what this means for the future of psychedelic-assisted therapy. Take an inside look at how PharmAla is shaping the next generation of clinical-grade entactogens.

We interviewed David E. Olson, Director of the UC Davis Institute for Psychedelics and Neurotherapeutics and Co-Founder of Delix Therapeutics, to discuss zalsupindole and the next generation of neuroplastogens: compounds designed to promote lasting neural plasticity without hallucinogenic effects. Join us as we explore how these molecules are reshaping psychiatry’s future.

We interviewed live Psilera's CEO & Co-Founder, Chris Witowski, PhD, to discuss next-generation psychedelics and their emerging indications in FTD and Anxiety Disorders.

Excited to have had Sam Banister, CSO and co-founder of Xylo Bio to explore targeted next-gen neurotherapeutics—with a focus on XYL-1001 and the broader potential of psychoplastogens.

We hosted a live LinkedIn conversation with Amir Lotfi, Senior Director of Pre-Clinical at Beckley Psytech, to discuss how cutting-edge translational models are shaping the next generation of psychedelic therapeutics — including the company’s lead candidate, BPL-003.